Alternative pharmacological strategies for adult ADHD treatment: a systematic review

  title={Alternative pharmacological strategies for adult ADHD treatment: a systematic review},
  author={Massimiliano Buoli and Marta Serati and Wiepke Cahn},
  journal={Expert Review of Neurotherapeutics},
  pages={131 - 144}
ABSTRACT Adult Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent psychiatric condition associated with high disability and frequent comorbidity. Current standard pharmacotherapy (methylphenidate and atomoxetine) improves ADHD symptoms in the short-term, but poor data were published about long-term treatment. In addition a number of patients present partial or no response to methylphenidate and atomoxetine. Research into the main database sources has been conducted to obtain an… 

Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

While available evidence addressed mainly the efficacy and tolerability of psychostimulants and non-psychostimULants for ADHD core symptoms in the short term, further empirical support is needed for the non-pharmacological and multimodal treatments.

ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan.

A systematic review of the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood.

Biological Predictors of Treatment Response in Adult Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review

Some biological markers seem promising for the prediction of treatment response in adults affected by ADHD, but further studies are needed to confirm the available data in the context of precision medicine.

Treatment-resistant attention-deficit hyperactivity disorder: Clinical significance, concept, and management

It is suggested that the more ideal strategy of defining treatment resistance should consider the improvement of ADHD symptoms and the global functioning simultaneously, and the optimal medication adjustment or the combination of medications and psychotherapy may be the potential therapeutic strategy for treatment-resistant ADHD.

ADHD: Reviewing the Causes and Evaluating Solutions

Given the heterogeneous etiology of ADHD, discussion is presented about the convenience of personalizing ADHD treatment, whether pharmacological or non-pharmacological, to reach an optimum effect in the majority of patients.

Adult attention deficit hyperactivity disorder and its management

Attention deficit hyperactivity disorder is a psychiatric condition that is increasingly recognised to occur in adulthood and has been associated with several negative outcomes, including depression,

Treatment strategies for ADHD: an evidence-based guide to select optimal treatment

An evidence-based appraisal of the literature on ADHD treatment is provided, supplemented by expert opinion on plausibility, and guidance for optimizing initiation of treatment and follow-up of patients in clinical settings is provided.

Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study

The top reasons for treatment changes among adults with ADHD are lack of efficacy and ADHD/treatment-related complications, highlighting the importance of developing more effective and safer treatments to alleviate the burden of ADHD.

Challenges and Limitations to Treating ADHD in Incarcerated Populations.

The standard treatments for ADHD, for prescribing in correctional institutions, barriers to using medications for off-label treatment of ADHD are reviewed, and future research is suggested that could better guide correctional treatment staff on how to approach patients with ADHD.

Anxiety and mood regulating treatment for adult attention deficit disorder

A case of 23-year-old man who presented with poor attention and gradual poor academic performance and was started on both daily treatment of Buproprion 150 mg daily, and Ritalin 10 mg PRN basis is highlighted.



Bupropion in adults with Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind study.

Bupropion can be an alternative medication for the treatment of Adults with ADHD as its clinical efficacy was proven by other studies and its theoretical and experimental evidence exists to support efficacy of this medication.

Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials

Overall, ATX had a clinically significant effect in adults with ADHD, with reductions in core symptoms and clinically meaningful responder rates.

Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder

This study shows that methylphenidate improves ADHD symptoms in adults in a dose-dependent fashion, and appears to be reduced in patients with co-morbid SUD.

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.

The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adults, while further validating the continuity of pharmacological responsivity of ADHD across the lifespan.

Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.

Extended-release mixed amphetamine salts in robust doses along with cognitive behavioral therapy are effective for treatment of co-occurring ADHD and cocaine use disorder, both improving ADHD symptoms and reducing cocaine use.

Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.

Venlafaxine may be a promising agent for the treatment of ADHD in adults and controlled clinical trials are needed to further examine this issue.

Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials

Methylphenidate was more efficacious than placebo for reducing ADHD symptoms and it was associated with a higher proportion of patients dropping out due to adverse effects and more attention should be given in the future to the endpoint “all-cause treatment discontinuation” when making regulatory decisions and developing clinical guidelines involving the treatment of ADHD in adulthood.

Comorbidities in Adult Attention-Deficit/Hyperactivity Disorder: A Practical Guide to Diagnosis in Primary Care

A review discusses disorders that may be comorbid with ADHD in adults, including anxiety, mood, substance use disorder, antisocial personality disorder, and borderline personality disorder.

Does serotonin deficit mediate susceptibility to ADHD?

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults

Preliminary evidence is provided that once-daily dosing with dasotraline, a long-acting, dual monoamine reuptake inhibitor, may be a safe and efficacious treatment for adult ADHD.